JLJiun-Yi Li

Jiun-Yi Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiun-Yi Li has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies

    by Wan-Jung Lu, Ritu Ojha, Mandeep Rana, Vinod Gautam, Jiun-Yi Li, Shao-An Wang

    Inflammation is a finely tuned host defense mechanism whose perpetual activation is a driver, promoter, and supporter of carcinogenesis. Key mediators of chronic inflammatory processes, viz. NF-kB, JAK-STAT, inflammasomes, reactive oxygen species (ROS), and cytokine network, if left unanswered, foster the tumour-supportive environment. Within the tumour microenvironment (TME), inflammatory cells, in combination with stromal and cancerous cells, modulate these pathways and regulate critical tumour hallmarks. Therefore, efforts have been made to understand and tackle the interface between the inflammation-cancer axis, but therapeutic outcomes remain limited. In this context, integrating systems-level biological insights with precision-driven medicinal chemistry may pave the way towards next-generation anti-inflammatory chemotherapeutics. The current review underlines the critical involvement of inflammation in cancer development by providing a comprehensive overview of key molecular pathways. A special emphasis was placed on understanding the medicinal chemistry campaign over the last 5 years for the development of inflammation-targeting small-molecule therapeutics in cancer.


  • Open Access

    Costunolide, a Sesquiterpene Lactone, Protects Against Platelet Activation and Thrombus Formation

    by Joen-Rong Sheu, Kuan-Hung Lin, Ray-Jade Chen, Hao-Ping Chia, Ting-Yu Chen, Thanasekaran Jayakumar, Hsueh-Hsiao Wang, Hsien-Yu Peng, Jiun-Yi Li, Wan-Jung Lu

    Background/Objectives: Circulating platelets mediate physiological hemostasis and are implicated in pathological thrombosis, which can cause vascular occlusion, leading to heart attacks or strokes. Costunolide is a sesquiterpene lactone extracted from Saussurea lappa. Although this lactone has multiple biological effects, including anti-inflammatory and antioxidant effects, that help slow the progression of atherosclerosis, its influence on platelet activation remains unclear. In this study, we examined the potential antiplatelet and antithrombotic effects of costunolide. Methods: We used platelet aggregation, flow cytometry, and Western blot analysis to examine its in vitro antiplatelet effects. Results: Our results indicated that costunolide inhibited platelet aggregation induced by collagen, but not by thrombin or the thromboxane A2 analog U46619, suggesting that costunolide selectively inhibits collagen-induced platelet activation. Additionally, costunolide blocked collagen-mediated granule release, calcium mobilization, and glycoprotein IIb/IIIa (GPIIb/IIIa) activation. Costunolide also inhibited phospholipase Cγ2 (PLCγ2), pleckstrin (a downstream target of protein kinase C), Akt, and mitogen-activated protein kinase. Moreover, it prevented collagen/epinephrine-induced pulmonary thrombosis and increased the survival rate of mice. Furthermore, costunolide delayed thrombus formation in the mesenteric vessels while it did not significantly affect hemostasis, suggesting it exhibits antithrombotic activity without bleeding tendency. These findings indicate that costunolide can block PLCγ2-PKC, Akt, and MAPK signaling pathways and subsequent granule release, calcium mobilization, and GPIIb/IIIa activation, eventually impeding platelet activation, platelet aggregation, and thrombus formation. Conclusions: In conclusion, besides its multiple biological activities that are beneficial for slowing the progression of atherosclerosis, we also demonstrated the antiplatelet and antithrombotic activities of costunolide. These effects highlight the therapeutic potential of costunolide in the treatment of patients with cardiovascular disease, particularly stroke and heart attack.


  • Open Access

    Comparative outcomes of robot-assisted, laparoscopic, and open radical nephrectomy: A Taiwan population-based study

    by Marcelo Chen, Yu-San Chien, Ching-Hu Chung, Jiun-Yi Li

    Objective Radical nephrectomy continues to be the established treatment for patients with large or locally advanced renal tumors. Although the use of robot-assisted techniques has grown substantially in recent years, their definitive advantages compared to traditional laparoscopic or open surgeries remain unclear. Materials and methods This retrospective, population-based analysis utilized data from the Taiwan Cancer Registry Database (TCRD) for patients who underwent open, laparoscopic, or robot-assisted radical nephrectomy between 2018 and 2020. Postoperative outcomes were assessed using the National Health Insurance Research Database (NHIRD), with follow-up information available through 2021. Results This study demonstrates that minimally invasive techniques (robotic-assisted RN (RARN) and laparoscopic RN (LRN)) were associated with lower blood transfusion rates, shorter length of hospital stays (LOS), and reduced ICU (intensive care unit) admissions compared to open radical nephrectomy (ORN), both before and after Inverse Probability of Treatment Weighting (IPTW) adjustment. Additionally, RARN showed a lower overall complication rate compared to ORN, though reoperation and readmission rates remained similar among all groups. Despite these perioperative advantages, no significant differences in overall survival were observed among the three surgical techniques. Conclusion The results of the study highlight the potential benefits of robotic and laparoscopic approaches in improving short-term surgical outcomes without compromising long-term survival. Interpretation is constrained by database limitations and residual selection bias.


  • Open Access

    Real-world outcomes of robotic and non-robotic hysterectomy for endometrial cancer: insights from a national cohort

    by Hui-Hsuan Lau, Yu-San Chien, Jiun-Yi Li, Ching-Hu Chung

    To compare perioperative outcomes, postoperative complications, and overall survival among patients with endometrial cancer (EC) undergoing open hysterectomy (OH), laparoscopic hysterectomy (LH), or robot-assisted hysterectomy (RAH) using nationwide real-world data. This was a retrospective, population-based study using 2018–2020 Taiwan Cancer Registry who underwent one of three surgical approaches (open, laparoscopic, or robot-assisted) and outcomes were evaluated using NHIRD with follow-up data available through 2021. From these linked datasets, we identified 5,360 women diagnosed with endometrial cancer who received hysterectomy, including 3,176 cases of OH, 1,760 LH, and 424 RAH. Inverse probability weighting (IPTW) methodology was utilized to harmonize baseline characteristics across the study arms. Compared with OH, RAH was associated with significantly fewer transfusions (15.5% vs. 29.7% (p < 0.0001)), shorter hospital stays (5.9 vs. 8.0 days, p < 0.0001), and reduced intensive care utilization. At one month postoperatively, overall complication rates were markedly lower in the RAH group (0.95%) than in OH (7.52%) and LH (6.07%) (both p < 0.0001). Specific complications, including vascular events, cardiac events, stroke, pneumonia, peritonitis, and wound disruption, were significantly reduced with RAH. Mortality analysis showed that OH was shown higher mortality hazard ratios compared with RAH (HR 1.39, 95% CI: 1.20–1.61 after IPTW), while survival outcomes were similar between RAH and LH (HR 0.97, 95% CI: 0.73–1.28). RAH for endometrial cancer demonstrated significant perioperative and postoperative advantages compared with OH, including lower complication rates and improved survival outcomes. RAH outcomes were largely comparable to laparoscopic hysterectomy. These findings support broader consideration of RAH as a safe and effective minimally invasive approach for EC management in real-world practice, although further long-term evaluation is warranted.


  • Open Access

    Comparison of outcomes of robot-assisted vs. open or laparoscopic of radical prostatectomy: a population-based cohort study

    by Chih-Chiao Lee, Marcelo Chen, Yu-San Chien, Ching-Hu Chung, Jiun-Yi Li

    We studied perioperative outcomes, postoperative complications, and survival rates for open radical prostatectomy (ORP), laparoscopic radical prostatectomy (LRP) and robot-assisted radical prostatectomy (RARP). Taiwan’s entire 2018–2021 National Health Insurance Research Database (NHIRD) was linked with the cancer registration file to conduct a retrospective cohort study. A total of 4883 patients with localized (or locally advanced) prostate cancer (PCa) who underwent ORP, RARP, or LRP from 2018 to 2021 were analyzed. Differences in patient characteristics and perioperative outcomes were assessed before and after inverse probability of treatment weighting (IPTW). RARP accounted for 91.3% of the surgeries, followed by LRP (4.7%) and ORP (4.3%). ORP and LRP were associated with higher blood transfusion rates, longer hospital stays, and ICU admissions compared with RARP. Post-IPTW, RARP exhibited significantly lower rates of perioperative complications and postoperative readmissions compared with ORP and LRP. The postoperative risk profile for RARP was lower compared with those for ORP and LRP.


  • Open Access

    Mid-term outcomes of robotic assisted versus conventional sternotomy for mitral valve replacement: a nationwide propensity-weighted analysis using Taiwan’s National Health Insurance Research Database

    by Yu-San Chien, Ching-Hu Chung, Jiun-Yi Li

    Background This study aimed to compare survival, complications, and healthcare costs between robotic-assisted and conventional sternotomy mitral valve replacement, using a nationwide population-based dataset from Taiwan. Methods Patients who underwent isolated surgical MVR between 2016 and 2021 were identified from Taiwan’s National Health Insurance Research Database. A total of 5,736 patients met inclusion criteria: 5,547 underwent conventional sternotomy MVR (CSMVR), and 113 received robot-assisted MVR (RAMVR). To reduce confounding, inverse probability of treatment weighting (IPTW) was applied using age, sex, and Charlson Comorbidity Index as covariates, yielding a weighted cohort of 5,660 CSMVR and 5,640 RAMVR cases for outcome analysis. Results After IPTW adjustment, RAMVR was associated with significantly better survival (hazard ratio: 0.37; 95% confidence interval: 0.33–0.41; p < 0.01), shorter hospital stay (16.5 vs. 22.7 days, p < 0.01), and shorter intensive care unit stay (4.4 vs. 9.1 days, p < 0.01). RAMVR patients also had lower rates of dialysis and stroke. One-year post-discharge medical costs were significantly lower in the RAMVR group (USD 1,640 vs. 4,003, p < 0.01). Although inpatient costs appeared lower for RAMVR, this reflects the exclusion of patient-borne expenses for robotic equipment not reimbursed by insurance. Conclusion In this national population-based analysis, RAMVR was associated with better mid-term survival, shorter hospital stays, and reduced medical costs compared with conventional sternotomy. These findings support the use of robotic-assisted surgery as a safe and effective alternative in selected patients undergoing mitral valve replacement.


  • Open Access

    Effect of Standardized Bundle Care and Bundle Compliance on Reducing Surgical Site Infections: A Pragmatic Retrospective Cohort Study

    by Yu-San Chien, Hsiang-Ting Chen, Hsiu-Tzy Chiang, Tz-Shin Luo, Hung-I Yeh, Jin-Cherng Sheu, Jiun-Yi Li

    Background: Care bundles for infection control consist of a set of evidence-based measures to prevent infections. This retrospective study aimed to compare surgical site infections (SSIs) from a single hospital surveillance system between 2017 and 2020, before and after implementing a standardized care bundle across specialties in 2019. It also aimed to assess whether bundle compliance affects the rate of SSIs. Material/Methods: A care bundle consisting of 4 components (peri-operative antibiotics use, peri-operative glycemic control, preoperative skin preparation, and maintaining intra-operative body temperature) was launched in 2019. We compared the incidence rates of SSIs, standardized infection ratio (SIR), and clinical outcomes of surgical procedures enrolled in the surveillance system before and after introducing the bundle care. The level of bundle compliance, defined as the number of fully implemented bundle components, was evaluated. Results: We included 6059 procedures, with 2010 in the pre-bundle group and 4049 in the post-bundle group. Incidence rates of SSIs (1.7% vs 1.0%, P=0.013) and SIR (0.8 vs 1.48, P<0.01) were significantly lower in the post-bundle group. The incidence of SSIs was significantly lower when all bundle components were fully adhered to, compared with when only half of the components were adhered to (0.3% vs 4.0%, P<0.01). Conclusions: SSIs decreased significantly after the application of a standardized care bundle for surgical procedures across specialties. Full adherence to all bundle components was the key to effectively reducing the risk of surgical site infections.


  • Open Access

    [Corrigendum] Nobiletin, a citrus flavonoid, activates vasodilator-stimulated phosphoprotein in human platelets through non‑cyclic nucleotide‑related mechanisms

    by Thanasekaran Jayakumar, Kao-Chang Lin, Wan-Jung Lu, Chia-Ying Lin, Geraldine Pitchairaj, Jiun-Yi Li, Joen-Rong Sheu

    Following the publication of the above paper, the authors noted that the first author affiliation was presented incorrectly. Essentially, 'School of Medicine' had been omitted from the address. Therefore, the author and affiliation details for this paper should have been presented as follows (the changes are highlighted in bold): THANASEKARAN JAYAKUMAR1*, KAO‑CHANG LIN1,2*, WAN-JUNG LU1,3, CHIA‑YING LIN4, GERALDINE PITCHAIRAJ5, JIUN‑YI LI4,6 and JOEN‑RONG SHEU1,4. 1Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei; 2Department of Neurology, Chi Mei Medical Center, Tainan; 3Department of Medical Research, Taipei Medical University Hospital; 4Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan, R.O.C.; 5Department of Animal Science, School of Life Sciences, Bharathidasan University, Tiruchirappalli, Tamil Nadu, India; Department of Cardiovascular Surgery, Mackay Memorial Hospital, and Mackay Medical College, Taipei, Taiwan, R.O.C. The authors regret that the error with the first author affiliation was not noticed prior to the publication of their paper, and apologize for any inconvenience caused. [The original article was published in International Journal of Molecular Medicine 39: 174‑182, 2017; DOI: 10.3892/ijmm.2016.2822].


  • Open Access

    [Corrigendum] Structure‑activity relationship of three synthesized benzimidazole‑based oligosaccharides in human platelet activation

    by Yi Chang, Wen-Hsien Hsu, Wen-Bin Yang, Thanasekaran Jayakumar, Tzu-Yin Lee, Joen-Rong Sheu, Wan-Jung Lu, Jiun-Yi Li

    Following the publication of the above paper, the authors noted that the third author affiliation was presented incorrectly. The third author affiliation should have been written as 'Department of Pharmacology, School of Medicine, College of Medicine, and Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 110, Taiwan'. Therefore, the author and affiliation details for this paper should have been presented as follows (the changes are highlighted in bold): YI CHANg1‑3*, WEN‑HsIEN HsU2,4*, WEN‑BIN YANg5, THANAsEKARAN JAYAKUMAR3, TZU‑YIN LEE3, JOEN‑RONg sHEU3, WAN‑JUNg LU3,6 and JIUN‑YI LI3,7. 1Department of Anesthesiology, Shin Kong Wu Ho‑Su Memorial Hospital, Taipei 111; 2School of Medicine, Fu‑Jen Catholic University, Xin Zhuang, New Taipei City 242; 3Department of Pharmacology, School of Medicine, College of Medicine, and Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 110; 4Department of Surgery, Wan‑Fang Hospital, Taipei Medical University, Taipei 116; 5Genomics Research Center, Academia Sinica, Taipei 115; 6Department of Medical Research and Translational Laboratory, Research Department, Taipei Medical University Hospital, Taipei 110; 7Department of Cardiovascular Surgery, Mackay Memorial Hospital, and Mackay Medical College, Taipei 104, Taiwan, R.O.C.. The authors regret that the error with the third author affiliation was not noticed prior to the publication of their paper, and apologize for any inconvenience caused. [The original article was published in International Journal of Molecular Medicine 40: 1520‑1528, 2017; DOI: 10.3892/ijmm.2017.3133].

  • Open Access

    Suppression of Human Platelet Activation via Integrin αIIbβ3 Outside-In Independent Signal and Reduction of the Mortality in Pulmonary Thrombosis by Auraptene

    by Chih-Wei Hsia, Cheng-Lin Tsai, Joen-Rong Sheu, Wan-Jung Lu, Chih-Hsuan Hsia, Marappan Velusamy, Thanasekaran Jayakumar, Jiun-Yi Li

    Auraptene is the most abundant coumarin derivative from plants. The pharmacological value of this compound has been well demonstrated, especially in the prevention of cancer and neurodegenerative diseases. Platelet activation is a major factor contributing to arterial thrombosis. Thus, this study evaluated the influence of auraptene in platelet aggregation and thrombotic formation. Auraptene inhibited platelet aggregation in human platelets stimulated with collagen only. However, auraptene was not effective in inhibiting platelet aggregation stimulated with thrombin, arachidonic acid, and U46619. Auraptene also repressed ATP release, [Ca2+]i mobilization, and P-selectin expression. Moreover, it markedly blocked PAC-1 binding to integrin αIIbβ3. However, it had no influence on properties related to integrin αIIbβ3-mediated outside-in signaling, such as the adhesion number, spreading area of platelets, and fibrin clot retraction. Auraptene inhibited the phosphorylation of Lyn-Fyn-Syk, phospholipase Cγ2 (PLCγ2), protein kinase C (PKC), Akt, and mitogen-activated protein kinases (MAPKs; extracellular-signal-regulated kinase (ERK1/2), and c-Jun N-terminal kinase (JNK1/2), but not p38 MAPK). Neither SQ22536, an adenylate cyclase inhibitor, nor ODQ, a guanylate cyclase inhibitor, reversed the auraptene-mediated inhibition of platelet aggregation. Auraptene reduced mortality caused by adenosine diphosphate (ADP)-induced pulmonary thromboembolism. In conclusion, this study provides definite evidence that auraptene signifies a potential therapeutic agent for preventing thromboembolic disorders.